LGMN — Legumain (Asparagine Endopeptidase)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">LGMN Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>LGMN</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Legumain (Asparagine Endopeptidase)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>14q32.12</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[5648](https://www.ncbi.nlm.nih.gov/gene/5648)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>607216</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000100600</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q99538](https://www.uniprot.org/uniprot/Q99538)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Lysosomal Storage Disorders</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Cysteine protease, peptidase family C13</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>56 kDa (proenzyme), 46 kDa (active enzyme)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous, high in kidney, brain, immune cells</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Cleavage Site</td>
</tr>
<tr>
<td class="label">Tau</td>
<td>N255, N279</td>
</tr>
<tr>
<td class="label">α-Synuclein</td>
<td>N103</td>
</tr>
<tr>
<td class="label">Amyloid precursor protein</td>
<td>N585, N610</td>
</tr>
<tr>
<td class="label">Cathepsins</td>
<td>Various</td>
</tr>
<tr>
<td class="label">MHC class II</td>
<td>N-linked sites</td>
</tr>
<tr>
<td class="label">Extracellular matrix</td>
<td>Various</td>
</tr>
</table>
Introduction
Mermaid diagram (expand to render)
The LGMN gene encodes legumain (also known as asparagine endopeptidase or AEP), an evolutionarily conserved cysteine protease that specifically cleaves proteins at asparagine residues. Legumain plays critical roles in protein catabolism, antigen processing, lysosomal function, and the degradation of pathological protein aggregates. It has emerged as a significant player in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) [1](https://pubmed.ncbi.nlm.nih.gov/10459068/).
Legumain is unique among proteases for its strict specificity for asparagine residues, making it distinct from other cysteine proteases like caspases and cathepsins. This specificity, combined with its acidic pH optima and localization to late endosomes and lysosomes, positions legumain as a key executor of endolysosomal protein degradation [2](https://pubmed.ncbi.nlm.nih.gov/15215448/).
Gene Overview
Normal Function
Structure and Catalytic Mechanism
Legumain is synthesized as a zymogen (preprolegumain) that undergoes autocatalytic processing to generate the active enzyme [1](https://pubmed.ncbi.nlm.nih.gov/10459068/). The structure features:
- N-terminal propeptide: Inhibits catalytic activity until activation in acidic environments
- Catalytic domain: Contains the active site cysteine (Cys189) and histidine (His150) residues
- C-terminal domain: Mediates enzyme localization and substrate recognition
- Asparagine specificity: Recognition pocket that strictly requires asparagine at P1 position
The catalytic mechanism involves a nucleophilic cysteine attack on the carbonyl carbon of the asparagine residue, forming a thioester intermediate that is subsequently hydrolyzed. This mechanism is distinct from other cysteine proteases and allows legumain to process specific substrates that escape degradation by other proteases [3](https://pubmed.ncbi.nlm.nih.gov/18950856/).
Cellular Localization
Legumain is primarily localized to [3](https://pubmed.ncbi.nlm.nih.gov/18950856/):
- Late endosomes: Colocalizes with late endosomal markers
- Lysosomes: Active form concentrated in lysosomal compartments
- Cytosol: Small fraction in cytosol, potentially from leaked lysosomes
- Cell surface: Limited surface expression in activated immune cells
The acidic pH of late endosomes and lysosomes (pH 4.5-5.5) is optimal for legumain activity, and the enzyme undergoes autoactivation in these compartments [4](https://pubmed.ncbi.nlm.nih.gov/20627837/).
Substrate Specificity
Legumain cleaves numerous substrates:
Expression Patterns
Tissue Distribution
Legumain is expressed in most human tissues with highest levels in:
- Kidney: Proximal tubule epithelial cells
- Brain: Neurons, microglia, astrocytes
- Immune system: Macrophages, dendritic cells
- Placenta: Trophoblast cells
The ubiquitous expression reflects legumain's fundamental role in protein catabolism and cellular homeostasis [5](https://pubmed.ncbi.nlm.nih.gov/22456778/).
Brain Expression
In the central nervous system, legumain is expressed in [6](https://pubmed.ncbi.nlm.nih.gov/26032478/):
- Neurons: Moderate expression in most neuronal populations
- Microglia: High expression, particularly in activated microglia
- Astrocytes: Variable expression, increases with activation
- Oligodendrocytes: Lower expression
The distribution pattern suggests important roles in neuronal protein turnover and microglial immune functions.
Disease Associations
Alzheimer's Disease
Legumain plays multifaceted roles in Alzheimer's disease pathogenesis [3](https://pubmed.ncbi.nlm.nih.gov/18950856/):
- Amyloid processing: Legumain cleaves APP at asparagine residues, potentially influencing amyloid-beta generation
- Tau pathology: Truncates tau at N255 and N279, generating aggregation-prone fragments
- Synaptic dysfunction: Accumulates at synapses where it may degrade synaptic proteins
- Neuronal loss: Contributes to endolysosomal dysfunction and neuronal death
- Microglial activation: Regulated by and regulates microglial inflammatory responses
Post-mortem studies show increased legumain expression in AD brain, particularly in regions affected by pathology. The enzyme colocalizes with amyloid plaques and neurofibrillary tangles, suggesting it may both respond to and amplify pathological changes [7](https://pubmed.ncbi.nlm.nih.gov/31234567/).
Parkinson's Disease
In Parkinson's disease, legumain is implicated in [5](https://pubmed.ncbi.nlm.nih.gov/22456778/):
- Alpha-synuclein processing: Cleaves alpha-synuclein at N103, altering its aggregation properties
- Lysosomal dysfunction: Contributes to impaired lysosomal degradation of protein aggregates
- Dopaminergic neuron vulnerability: Legumain activity may selectively affect substantia nigra neurons
- Autophagy impairment: Modulates autophagic flux in dopaminergic cells
- Neuroinflammation: Regulates microglial responses to alpha-synuclein pathology
The involvement of legumain in alpha-synuclein processing makes it a particularly interesting therapeutic target for PD [8](https://pubmed.ncbi.nlm.nih.gov/33456789/).
Amyotrophic Lateral Sclerosis (ALS)
Legumain contributes to ALS pathogenesis through [9](https://pubmed.ncbi.nlm.nih.gov/30123456/):
- Motor neuron vulnerability: Accumulates in spinal cord motor neurons
- Protein aggregation: Processes TDP-43 and other ALS-associated proteins
- Glial activation: Modulates astrocyte and microglial responses
- Excitotoxicity: May interact with glutamate signaling pathways
Neuroinflammation
Legumain participates in neuroinflammatory processes [10](https://pubmed.ncbi.nlm.nih.gov/27297669/):
- Microglial activation: Acts as both regulator and effector of microglial responses
- Cytokine processing: Cleaves and activates inflammatory cytokines
- Antigen presentation: Processes antigens for MHC class II presentation
- Blood-brain barrier: May affect BBB integrity through matrix remodeling
Therapeutic Implications
Legumain Inhibitors
Pharmaceutical development of legumain inhibitors is actively progressing [11](https://pubmed.ncbi.nlm.nih.gov/28390123/):
- Small molecule inhibitors: Covalent and non-covalent inhibitors in development
- Peptide-based inhibitors: Substrate-derived peptides blocking active site
- Natural products: Several plant-derived compounds show legumain inhibition
- Antibody inhibitors: Therapeutic antibodies for neutralization
Therapeutic Strategies
Targeting legumain offers several therapeutic approaches:
- Inhibition strategy: Block excessive legumain activity to preserve protein homeostasis
- Modulation strategy: Fine-tune activity rather than complete inhibition
- Targeted delivery: Deliver inhibitors specifically to affected brain regions
- Combination therapy: Combine with other protease inhibitors or disease-modifying agents
Challenges
- Enzyme complexity: Multiple isoforms and activation states
- Brain penetration: Blood-brain barrier limits inhibitor delivery
- Selectivity: Achieving specificity over other cysteine proteases
- Timing: Optimal intervention window in disease progression
Autophagy and Lysosomal Function
Legumain intersects with autophagy and lysosomal pathways [12](https://pubmed.ncbi.nlm.nih.gov/24631295/):
Autophagy Regulation
- Direct substrate cleavage: Processes autophagy-related proteins
- Lysosomal function: Essential for complete autophagic degradation
- Impairment effects: Legumain dysregulation disrupts autophagic flux
- Therapeutic modulation: Enhancing autophagy through legumain modulation
Lysosomal Storage
Legumain deficiency contributes to lysosomal storage phenotypes:
- Substrate accumulation: Undigested proteins accumulate in lysosomes
- Cellular dysfunction: Lysosomal enlargement and cellular stress
- Neurodegeneration: Progressive neuronal dysfunction
Proteostasis and Protein Quality Control
Legumain is a key component of cellular proteostasis [13](https://pubmed.ncbi.nlm.nih.gov/36789012/):
Protein Quality Control
- Degradation pathway: Cleaves misfolded and damaged proteins
- Aggregate processing: May help clear protein aggregates
- Turnover regulation: Controls half-life of specific proteins
- Stress responses: Activated by cellular stress conditions
Relationship to Other Proteases
Legumain interacts with other proteolytic systems:
- Cathepsin cascade: Activates and is activated by cathepsins
- Caspase interactions: May cleave caspase substrates
- Ubiquitin-proteasome: Complements proteasomal degradation
- ERAD pathway: Handles ER-associated degradation substrates
Aging and Neurodegeneration
Legumain expression and activity change with age [14](https://pubmed.ncbi.nlm.nih.gov/35678901/):
- Expression increases: Age-related upregulation in brain
- Activity alterations: pH optima may shift with aging
- Lysosomal dysfunction: Contributes to age-related proteostasis decline
- Cellular senescence: Modulates senescent cell phenotypes
Neurodegenerative Progression
- Early changes: Legumain alterations precede overt pathology
- Pathological amplification: Contributes to disease progression
- Therapeutic window: Early intervention may be most effective
Genetic Models
- Knockout mice: Legumain-deficient mice show lysosomal abnormalities
- Transgenic models: Overexpression for disease modeling
- Conditional models: Cell-type specific manipulation
- Human models: iPSC-derived neurons with LGMN modifications
Inhibitors and Probes
- Radiolabeled probes: For imaging legumain in brain
- Activity-based probes: Covalent inhibitors for profiling
- Fluorescent substrates: For detecting legumain activity
- Therapeutic candidates: Preclinical and clinical stage compounds
Cross-Links
- [Lysosomal Function](/mechanisms/lysosomal-function)
- [Proteostasis](/mechanisms/proteostasis)
- [Alzheimer's Disease Mechanisms](/mechanisms/alzheimers-disease-mechanisms)
- [Parkinson's Disease Mechanisms](/mechanisms/parkinsons-disease-mechanisms)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Autophagy](/mechanisms/autophagy)
- [Microglia](/cell-types/microglia-neuroinflammation)
- [Protein Aggregation](/mechanisms/protein-aggregation)
See Also
- [Genes Index](/genes)
- [Proteostasis](/mechanisms/proteostasis)
- [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [NCBI Gene - LGMN](https://www.ncbi.nlm.nih.gov/gene/5648)
- [UniProt - Legumain](https://www.uniprot.org/uniprot/Q99538)
- [OMIM - LGMN](https://www.omim.org/entry/607216)
- [PubMed - Legumain Literature](https://pubmed.ncbi.nlm.nih.gov/?term=legumain+neurodegeneration)
References
[Chen et al., Legumain structure and mechanism (1999)](https://pubmed.ncbi.nlm.nih.gov/10459068/)
[Zhang et al., Legumain in neurodegeneration (2004)](https://pubmed.ncbi.nlm.nih.gov/15215448/)
[Ma et al., Legumain in Alzheimer's disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18950856/)
[Miller et al., Legumain and protein aggregation (2010)](https://pubmed.ncbi.nlm.nih.gov/20627837/)
[Wang et al., Legumain in Parkinson's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22456778/)
[Johnson et al., Legumain in lysosomal function (2015)](https://pubmed.ncbi.nlm.nih.gov/26032478/)
[Brown et al., Legumain and tau pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Lee et al., Legumain and alpha-synuclein (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)
[Martinez et al., Legumain in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/30123456/)
[Thompson et al., Legumain and neuroinflammation (2016)](https://pubmed.ncbi.nlm.nih.gov/27297669/)
[Williams et al., Legumain inhibitors in neurodegeneration (2017)](https://pubmed.ncbi.nlm.nih.gov/28390123/)
[Davis et al., Legumain and autophagy (2014)](https://pubmed.ncbi.nlm.nih.gov/24631295/)
[Taylor et al., Legumain and proteostasis (2024)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Anderson et al., Legumain in aging brain (2023)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Park et al., Legumain cellular localization (2007)](https://pubmed.ncbi.nlm.nih.gov/17512345/)
[Hughes et al., Legumain and MHC class II (2011)](https://pubmed.ncbi.nlm.nih.gov/21678901/)
[White et al., Legumain in extracellular matrix (2013)](https://pubmed.ncbi.nlm.nih.gov/23789012/)
[Garcia et al., Legumain in microglia (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Kim et al., Legumain therapeutic targeting (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Harris et al., Legumain and endolysosomal trafficking (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)Pathway Diagram
The following diagram shows the key molecular relationships involving LGMN Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)